Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)

NCT00726856 · clinicaltrials.gov ↗

COMPLETED

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate

Sponsor

Organon and Co